001     288814
005     20241220114044.0
024 7 _ |a 10.1007/s00018-024-05126-1
|2 doi
024 7 _ |a pmid:38436764
|2 pmid
024 7 _ |a pmc:PMC10912141
|2 pmc
024 7 _ |a 1420-682X
|2 ISSN
024 7 _ |a 0014-4754
|2 ISSN
024 7 _ |a 1420-9071
|2 ISSN
024 7 _ |a altmetric:160329026
|2 altmetric
037 _ _ |a DKFZ-2024-00485
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Liu, Kaijing
|b 0
245 _ _ |a Dynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication.
260 _ _ |a Cham (ZG)
|c 2024
|b Springer International Publishing AG
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1726657409_8429
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The Hippo pathway and its transcriptional effectors yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are targets for cancer therapy. It is important to determine if the activation of one factor compensates for the inhibition of the other. Moreover, it is unknown if YAP/TAZ-directed perturbation affects cell-cell communication of non-malignant liver cells.To investigate liver-specific phenotypes caused by YAP and TAZ inactivation, we generated mice with hepatocyte (HC) and biliary epithelial cell (BEC)-specific deletions for both factors (YAPKO, TAZKO and double knock-out (DKO)). Immunohistochemistry, single-cell sequencing, and proteomics were used to analyze liver tissues and serum.The loss of BECs, liver fibrosis, and necrosis characterized livers from YAPKO and DKO mice. This phenotype was weakened in DKO tissues compared to specimens from YAPKO animals. After depletion of YAP in HCs and BECs, YAP expression was induced in non-parenchymal cells (NPCs) in a cholestasis-independent manner. YAP positivity was detected in subgroups of Kupffer cells (KCs) and endothelial cells (ECs). The secretion of pro-inflammatory chemokines and cytokines such as C-X-C motif chemokine ligand 11 (CXCL11), fms-related receptor tyrosine kinase 3 ligand (FLT3L), and soluble intercellular adhesion molecule-1 (ICAM1) was increased in the serum of YAPKO animals. YAP activation in NPCs could contribute to inflammation via TEA domain transcription factor (TEAD)-dependent transcriptional regulation of secreted factors.YAP inactivation in HCs and BECs causes liver damage, and concomitant TAZ deletion does not enhance but reduces this phenotype. Additionally, we present a new mechanism by which YAP contributes to cell-cell communication originating from NPCs.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Cholangiocyte
|2 Other
650 _ 7 |a Endothelial cell
|2 Other
650 _ 7 |a Hepatocyte
|2 Other
650 _ 7 |a Hippo pathway
|2 Other
650 _ 7 |a Kupffer cell
|2 Other
650 _ 7 |a Liver damage
|2 Other
650 _ 7 |a Proteomics
|2 Other
650 _ 7 |a Single-cell analysis
|2 Other
650 _ 7 |a TAZ
|2 Other
650 _ 7 |a Ligands
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Endothelial Cells
|2 MeSH
650 _ 2 |a Ligands
|2 MeSH
650 _ 2 |a Liver
|2 MeSH
650 _ 2 |a Hepatocytes
|2 MeSH
650 _ 2 |a Cell Communication
|2 MeSH
700 1 _ |a Wehling, Lilija
|b 1
700 1 _ |a Wan, Shan
|b 2
700 1 _ |a Weiler, Sofia M E
|b 3
700 1 _ |a Tóth, Marcell
|b 4
700 1 _ |a Ibberson, David
|b 5
700 1 _ |a Marhenke, Silke
|b 6
700 1 _ |a Ali, Adnan
|0 P:(DE-He78)86c8c6c90abd00c209e39736da1ec1fd
|b 7
|u dkfz
700 1 _ |a Lam, Macrina
|0 P:(DE-He78)1c6d6ca22cc31cb79e6e1f5277ef06e0
|b 8
|u dkfz
700 1 _ |a Guo, Te
|b 9
700 1 _ |a Pinna, Federico
|b 10
700 1 _ |a Pedrini, Fabiola
|b 11
700 1 _ |a Damle-Vartak, Amruta
|b 12
700 1 _ |a Dropmann, Anne
|b 13
700 1 _ |a Rose, Fabian
|b 14
700 1 _ |a Colucci, Silvia
|b 15
700 1 _ |a Cheng, Wenxiang
|b 16
700 1 _ |a Bissinger, Michaela
|b 17
700 1 _ |a Schmitt, Jennifer
|b 18
700 1 _ |a Birner, Patrizia
|b 19
700 1 _ |a Poth, Tanja
|b 20
700 1 _ |a Angel, Peter
|0 P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9
|b 21
|u dkfz
700 1 _ |a Dooley, Steven
|b 22
700 1 _ |a Muckenthaler, Martina U
|b 23
700 1 _ |a Longerich, Thomas
|b 24
700 1 _ |a Vogel, Arndt
|b 25
700 1 _ |a Heikenwälder, Mathias
|0 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5
|b 26
|u dkfz
700 1 _ |a Schirmacher, Peter
|b 27
700 1 _ |a Breuhahn, Kai
|0 0000-0002-2462-1229
|b 28
773 _ _ |a 10.1007/s00018-024-05126-1
|g Vol. 81, no. 1, p. 115
|0 PERI:(DE-600)1458497-9
|n 1
|p 115
|t Cellular and molecular life sciences
|v 81
|y 2024
|x 1420-682X
856 4 _ |u https://inrepo02.dkfz.de/record/288814/files/s00018-024-05126-1.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/288814/files/s00018-024-05126-1.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:288814
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)86c8c6c90abd00c209e39736da1ec1fd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)1c6d6ca22cc31cb79e6e1f5277ef06e0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 26
|6 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1120
|2 StatID
|b BIOSIS Reviews Reports And Meetings
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
920 1 _ |0 I:(DE-He78)F180-20160331
|k F180
|l Chronische Entzündung und Krebs
|x 0
920 1 _ |0 I:(DE-He78)D440-20160331
|k D440
|l Chronische Entzündung und Krebs
|x 1
920 1 _ |0 I:(DE-He78)A100-20160331
|k A100
|l A100 Signaltransduktion/ Wachstumskontrolle
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F180-20160331
980 _ _ |a I:(DE-He78)D440-20160331
980 _ _ |a I:(DE-He78)A100-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21